Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06984861 · ClinicalTrials.gov registry record · Phase 2
A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer
A Phase 2 study of Oropharyngeal Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
- 7
- Study locations
NCT06984861: Recruiting Phase 2 study of Oropharyngeal Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06984861 is a Phase 2 study of Oropharyngeal Carcinoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 74 participants, below the 220-participant average among 7 other Oropharyngeal Carcinoma trials with a reported enrollment target (66% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06984861, a Phase 2 study of Oropharyngeal Carcinoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study is to find out if lower doses (given in fewer treatments over a shorter period of time) of radiation therapy in combination with standard-of-care chemotherapy is an effective treatment for people with Human Papilloma Virus (HPV)-positive throat cancer and works as well as the standard doses of radiation therapy in combination with standard-of-care chemotherapy. The chemotherapy drugs used in combination with radiation therapy in this study include cisplatin, carboplatin, and 5-fluorouracil (5-FU).
Conditions Studied
Interventions
- OTHER Questionnaires
- COMBINATION_PRODUCT Chemoradiation
- DIAGNOSTIC_TEST 18F-FMISO PET/CT Scan
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2028-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06984861
The ClinicalTrials.gov registry entry for NCT06984861 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 220-participant average among 7 other Oropharyngeal Carcinoma trials with a reported enrollment target (66% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Oropharyngeal Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Questionnaires is the first listed.
NCT06984861 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06984861 about?
NCT06984861 is a clinical study titled "A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer". The researchers are doing this study is to find out if lower doses (given in fewer treatments over a shorter period of time) of radiation therapy in combination with standard-of-care chemotherapy is an effective treatment for people with Human Papilloma Virus (HPV)-positive throat cancer and works a...
What is the current status of trial NCT06984861?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2025-05-13. Estimated completion is 2028-05.
What conditions does trial NCT06984861 study?
This clinical trial studies the following conditions: Oropharyngeal Carcinoma.
What interventions are being tested in trial NCT06984861?
The interventions under investigation include: Questionnaires (OTHER), Chemoradiation (COMBINATION_PRODUCT), 18F-FMISO PET/CT Scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06984861?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06984861 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharyngeal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
RECRUITING · Phase 2
-
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
RECRUITING · Phase 2
-
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
RECRUITING · Phase 2
-
Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma
RECRUITING
-
High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors
ACTIVE NOT RECRUITING · Phase 1
-
Patient Reported Outcome Post Radiation Therapy or Chemoradiotherapy Patient Care in Patients With Oropharyngeal Cancer
ACTIVE NOT RECRUITING
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.